胰腺癌血清微RNA-486-3p的异常表达及对细胞增殖、凋亡的影响
收稿日期: 2020-12-04
网络出版日期: 2022-07-26
The serum level of microRNA-486-3p and its effects on proliferation and apoptosis of pancreatic cancer cells
Received date: 2020-12-04
Online published: 2022-07-26
目的：研究胰腺癌患者血清微RNA（microRNA,miRNA/miR）-486-3p的表达情况及其在体外实验中对人胰腺癌细胞增殖、凋亡的影响。方法：于消化科、胰腺外科及老年科病房收集确诊胰腺癌患者21例为试验组,20名健康成人为对照组,留取外周血并分离血清,实时定量聚合酶链反应（polymerase chain reaction,PCR）检测血清中miR-486-3p的表达水平;体外实验采用细胞计数试剂盒8（cell-counting kit 8,CCK-8）法和流式细胞仪分别检测miR-486-3p对人胰腺癌细胞增殖、细胞凋亡的影响。结果：与健康对照组相比,胰腺癌患者血清中miR-486-3p的表达水平明显升高（50.73±0.82比34.80±0.74,P<0.05）; 体外实验中采用干扰小RNA（small interfering RNA,siRNA）瞬时转染的方法增高miR-486-3p的表达,使得人胰腺癌细胞SW1990和PANC-1的增殖能力明显增强（2.77±0.07比2.05±0.06,P<0.05;2.81±0.04比1.89±0.04,P<0.05）;抑制miR-486-3p则可明显减少胰腺癌细胞的增殖（1.71±0.03比2.07±0.05,P<0.05;1.61±0.03比2.20±0.07,P<0.05）;增高miR-486-3p的表达可明显减少细胞凋亡（24.1%±1.14%比45.9%±1.11%,P<0.05;21.9%±0.25%比42.3%±1.62%,P<0.05）。结论：胰腺癌患者血清中miR-486-3p较健康对照组明显升高,可促进胰腺癌细胞的增殖并抑制细胞凋亡而发挥促癌作用。
关键词： 胰腺癌; 血清微RNA-486-3p; 细胞增殖和凋亡
李晓丽, 李为光, 钱爱华, 曹国良 . 胰腺癌血清微RNA-486-3p的异常表达及对细胞增殖、凋亡的影响[J]. 内科理论与实践, 2021 , 16(02) : 121 -125 . DOI: 10.16138/j.1673-6087.2021.02.011
Objective To investigate the serum level of microRNA-486-3p (miR-486-3p) and its effects on proliferation and apoptosis of pancreatic cancer cells. Methods Twenty-one patients with pancreatic cancer and twenty healthy controls were enrolled. Real-time polymerase chain reaction(PCR) was used to detect the serum miR-486-3p. The effects of miR-486-3p on pancreatic cancer cells proliferation and apoptosis were respectively examined by cell counting kit 8(CCK8) assay and flow cytometry assay. Results Compared with healthy controls,serum level of miR-486-3p was significantly up-regulated in patients with pancreatic cancer （50.73±0.82 vs 34.80±0.74, P<0.05）; The proliferation of pancreatic cancer cells were significantly up-regulated （SW1990: 2.77±0.07 vs 2.05±0.06, P<0.05; PANC-1: 2.81±0.04 vs1.89±0.04, P<0.05） and the apoptosis rates were suppressed by forced expression of miR-486-3p（24.1%±1.14% vs 45.9%±1.11%, P<0.05; 21.9%±0.25% vs 42.3%±1.62%, P<0.05）, while inhibition of miR-486-3p significantly down-regulated the proliferation of pancreatic cancer cells（SW1990: 1.71±0.03 vs 2.07±0.05, P<0.05; PANC-1: 1.61±0.03 vs 2.20±0.07, P<0.05）. Conclusions The serum miR-486-3p were significantly up-regulated in patients with pancreatic cancer; MiR-486-3p may function as a tumor-promoter by promoting cell proliferation and suppressing apoptosis in pancreatic cancer cells.
| [1] | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. |
| [2] | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1), 7-30. |
| [3] | Kuroczycki-Saniutycz S, Grzeszczuk A, Zwierz ZW, et al. Prevention of pancreatic cancer[J]. Contemp Oncol (Pozn), 2017, 21(1): 30-34. |
| [4] | Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma[J]. N Engl J Med, 2014, 371(11): 1039-1049. |
| [5] | Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer[J]. Nat Rev Cancer, 2018, 18(1): 5-18. |
| [6] | Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222. |
| [7] | Li Z, Xu R, Li N. MicroRNAs from plants to animals, do they define a new messenger for communication[J]?. Nutr Metab, 2018, 15: 68. |
| [8] | Hayder H, O’Brien J, Nadeem U, et al. MicroRNAs: crucial regulators of placental development[J]. Reproduction, 2018, 155(6): 259-271. |
| [9] | Chou ST, Peng HY, Mo KC, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1[J]. J Exp Clin Cancer Res, 2019, 38(1): 281. |
| [10] | Ye HQ, Yu XL, Xia JY, et al. MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer[J]. Biomed Pharmacother, 2016, 80: 109-114. |
| [11] | Li WG, Yuan YZ, Qiao MM, et al. High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells[J]. World J Gastroenterol, 2012, 18(21): 2630-2639. |
| [12] | Yu J, Li A, Hong SM, et al. MicroRNA alterations of pancreatic intraepithelial neoplasias[J]. Clin Cancer Res, 2012, 18(4): 981-992. |
| [13] | Fest J, Ruiter R, van Rooij FJ, et al. Underestimation of pancreatic cancer in the national cancer registry - reconsidering the incidence and survival rates[J]. Eur J Cancer, 2017, 72: 186-191. |
| [14] | Bouvier AM, Bossard N, Colonna M, et al. Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study[J]. Eur J Cancer Prev, 2017, 26: S63-S69. |
| [15] | Zhang S, Ng MK. Gene-microRNA network module ana-lysis for ovarian cancer[J]. BMC Syst Biol, 2016, 10 Suppl 4: 117. |
| [16] | Beheshti A, Vanderburg C, McDonald JT, et al. A circulating microRNA signature predicts age-based development of lymphoma[J]. PLoS One, 2017, 12(1): e0170521. |
| [17] | Shigeyasu K, Toden S, Zumwalt TJ, et al. Emerging role of microRNAs as liquid biopsy biomarkers in gastrointestinal cancers[J]. Clin Cancer Res, 2017, 23(10): 2391-2399. |
| [18] | Youness RA, El-Tayebi HM, Assal RA, et al. MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc[J]. Oncol Lett, 2016, 12(4): 2567-2573. |
| [19] | Gu Y, Zhang X, Yang Q, et al. Aberrant placental villus expression of miR-486-3p and miR-3074-5p in recurrent miscarriage patients and uterine expression of these microRNAs during early pregnancy in mice[J]. Gynecol Obstet Invest, 2015. [Epub ahead of print]. |
| [20] | Peng X, Wei F, Hu X. Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p[J]. J Cell Biochem, 2020, 121(2): 1953-1962. |
| [21] | Jin X, Pang W, Zhang Q, et al. MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial-mesenchymal transition by targeting twinfilin actin binding protein 1[J]. J Int Med Res, 2019, 47(8): 3745-3756. |
| [22] | Yang S, Sui J, Liu T, et al. Expression of miR-486-5p and its significance in lung squamous cell carcinoma[J]. J Cell Biochem, 2019, 120(8): 13912-13923. |
| [23] | Liu X, Chen X, Zeng K, et al. DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/β-catenin signal pathways[J]. Cell Death Dis, 2018, 9(10): 1037. |
| [24] | Chen H, Ren C, Han C, et al. Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma[J]. PLoS One, 2015, 10(3): e0119384. |
| [25] | Balogh J, Victor D 3rd, Asham EH, Burroughs SG, et al. Hepatocellular carcinoma: a review[J]. J Hepatocell Carcinoma, 2016, 3: 41-53. |
| [26] | Li H, Mou Q, Li P, et al. MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1[J]. J Cancer, 2019, 10(19): 4695-4706. |
| [27] | Yang Y, Ji C, Guo S, et al. The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways[J]. Oncotarget, 2017, 8(42): 72835-72846. |
| [28] | Hummel R, Wang T, Watson DI, et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer[J]. Oncol Rep, 2011, 26(4): 1011-1017. |
| [29] | Swierniak M, Wojcicka A, Czetwertynska M, et al. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2013, 98(8): E1401-E1409. |
| [30] | Mosakhani N, Sarhadi VK, Borze I, et al. MicroRNA profiling differentiates colorectal cancer according to KRAS status[J]. Genes Chromosomes Cancer, 2012, 51(1): 1-9. |
| [31] | Huang YH, Lin KH, Chen HC, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma[J]. PLOS One, 2012, 7(5): e37188. |
/
| 〈 |
|
〉 |
